The Vanguard Group, Inc. has recently announced that it has increased stake in Myriad Genetics, Inc. (NASDAQ:MYGN) by 0.09%. After grabbing 9.02 million shares, the institutional investor is now in possession of 7970.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 11.02% having worth around $140.56 million. Moreover, Wellington Management Co. LLP increased its share by 0.25 million to have a control over 6.0 million shares. And Millennium Management LLC raised its holdings to 0.78 million shares by acquiring 4.26 million shares or 5.20% of the stake.
Myriad Genetics, Inc. (MYGN) concluded trading on 11/22/23 at a closing price of $17.70, with 0.49 million shares of worth about $8.74 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -22.84% during that period and on Wednesday the price saw a gain of about 1.26%. Currently the company’s common shares owned by public are about 81.20M shares, out of which, 78.94M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 9 analysts are covering the MYGN stock and their offered price forecasts bring an average price target of $19.71. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $28.00 and could fall to a lowest price of $12.00. The stock’s current price level is 13.15% above of average price target set by the analysts, while a rise to estimated low would result in loss of -47.5% for the stock. However, touching the estimated high of $28.00 would mean a gain of 36.79% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 67 times over the past 12 months. They bought 570,333 shares in 20 of the transactions. In 47 selling transactions, insiders dumped 280,415 shares.
iShares Core S&P Small Cap ETF, Vanguard Explorer Fund, and Vanguard Total Stock Market ETF are the top 3 mutual funds which are holding stakes in Myriad Genetics, Inc. iShares Core S&P Small Cap ETF is currently holding 5.51 million shares of worth totaling $85.83 million. The company recently came selling 18852.0 shares which brought its stake up to 6.73% of the company’s outstanding shares. Vanguard Explorer Fund bought 0.2 million shares, after which its hold over company’s outstanding shares expand to 4.15%, leaving 3.4 million shares with the mutual fund that have a worth of about $52.97 million. Vanguard Total Stock Market ETF, after buying 2.43 million shares, have now control over 2.97% of the stake in the company. It holds 7073.0 shares of worth $37.86 million.
Myriad Genetics, Inc. (NASDAQ: MYGN) started trading at $17.76, above $0.28 from concluding price of the previous day. However, the stock later moved at a day high price of 17.89, or with a gain of 1.26%. Stock saw a price change of 1.61% in past 5 days and over the past one month there was a price change of 13.46%. Year-to-date (YTD), MYGN shares are showing a performance of 21.98% which decreased to -8.43% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $13.82 but also hit the highest price of $24.21 during that period. The average intraday trading volume for Myriad Genetics, Inc. shares is 612.77K. The stock is currently trading 8.03% above its 20-day simple moving average (SMA20), while that difference is up 10.49% for SMA50 and it goes to -10.22% lower than SMA200.
The Vanguard Group, Inc. acquired 9.02 million shares of Myriad Genetics, Inc. having value of about $140.56 million. Data submitted at the U.S SEC by The Vanguard Group, Inc. revealed that the firm now holds 7970.0 shares in the company valued at close to $141069.0, or have control over 0.09% stake in the company. Myriad Genetics, Inc. (NASDAQ: MYGN) currently have 81.20M outstanding shares and institutions hold larger chunk of about 102.13% of that. Holding of mutual funds in the company is about 52.51% while other institutional holders and individual stake holders have control over 8.21% and 50.17% of the stake respectively.
The stock has a current market capitalization of $1.45B and its 3Y-monthly beta is at 1.84. It has posted earnings per share of -$3.36 in the same period. It has Quick Ratio of 1.15 while making debt-to-equity ratio of 0.29. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MYGN, volatility over the week remained 3.88% while standing at 5.57% over the month.
Analysts are in expectations that Myriad Genetics, Inc. (MYGN) stock would likely to be making an EPS of $0.01 in the current quarter, while forecast for next quarter EPS is -$0.03 and it is $0.05 for next year. For the current quarter EPS, analysts have given the company a lowest target $0.01 which is $0.02 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.12 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -1.25% while it is estimated to increase by 134.57% in next year.
Analysts at 9 brokerage firms have issued recommendations for the Myriad Genetics, Inc. (MYGN)’s stock and average of those rates the stock at a “Hold” and assign it a score of 3.22. Out of those 9 Wall Street analysts, 1 recommended a “Buy” rating, while 4 were in favor recommending the stock as a “Hold” and 2 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by JP Morgan on July 05, 2023 offering an Underweight rating for the stock and assigned a target price of $18 to it.
